A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Genmab
Radiopharm Theranostics, Ltd
M.D. Anderson Cancer Center
Bristol-Myers Squibb
AstraZeneca
Eisai Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
AstraZeneca
NeoImmuneTech
Sumitomo Pharma America, Inc.
Genmab
Exscientia AI Limited
Amgen
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Jacobio Pharmaceuticals Co., Ltd.
Transgene
BicycleTx Limited
Immunitas Therapeutics
Hadassah Medical Organization
A2 Biotherapeutics Inc.
TCR2 Therapeutics
Incyte Corporation
Cancer Research UK
MacroGenics
NuCana plc
University of California, Irvine
Medicenna Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Formation Biologics
Bristol-Myers Squibb
Numab Therapeutics AG
SK Life Science, Inc.
Kymab Limited
BioAtla, Inc.
Cyteir Therapeutics, Inc.
Sellas Life Sciences Group
Simcha IL-18, Inc.
Mundipharma Research Limited
Salubris Biotherapeutics Inc
CytosinLab Therapeutics Co., Ltd.
Cantargia AB
Cancer Research UK
Pfizer
Innolake Biopharm
TransThera Sciences (Nanjing), Inc.
Fred Hutchinson Cancer Center
Genmab